Farnesylated tetrahydro-naphthalenols as hypolipidemic agents
AssigneeBristol-Myers Squibb Company
InventorBradley C. Pearce
Life of this patent
Estimating the term…
Abstract
The invention relates to novel farnesylated tetrahydro-naphthalenols, that inhibit HMGR activity which results in a decrease in serum total cholesterol, a decrease in LDL cholesterol levels, and inhibition of LDL oxidation. The farnesylated tetrahydro-naphthalenols of the present invention are thus useful for cholesterol/lipid lowering in cases of hypercholesterolemia, hyperlipidemia, and atherosclerosis.
Claims6
The compound having the structural formula (II) ##STR6## wherein R.sub.3 is a physiologically hydrolyzable ester;
- R.sub.1 represents hydrogen, C.sub.1 -C.sub.10 lower alkyl, halogen, or OMe;
- R.sub.2 represents hydrogen, C.sub.1 -C.sub.10 lower alkyl;
- and
- n is 1-3;
- or pharmaceutically acceptable acid addition salts, metal salts or solvates thereof.
The method of treating hyperlipidemia hypercholesterolemia, and LDL oxidation in a bird of mammal, which comprises administering to said bird or mammal a safe and effective amount of at least one compound having the Formula (II) ##STR7## wherein R.sub.3 is a physiologically hydrolyzable ester;
- R.sub.1 represents hydrogen, C.sub.1 -C.sub.10 lower alkyl, halogen or OMe;
- R.sub.2 represents hydrogen, C.sub.1 -C.sub.10 lower alkyl;
- and
- n is 1-3.
Dependencies are inferred from the claim text.